29 Jul 2015
(MENAFN) Jordan’s Hikma Pharmaceuticals said it is buying US generic drugs business of Boehringer Ingelheim for USD2.65 billion in a cash-and-stock deal, Arab News reported.
Hikma Pharmaceuticals, which produces and markets branded and non-branded generic and injectable drugs, said the Boehringer purchase would make it the sixth biggest provider of generic drugs in the US.
The move comes as the Jordanian firm is looking to expand in the US. It strengthened its injectable drugs business there when it bought manufacturing assets from Germany’s Boehringer last year.
“We won’t be the size of Teva and other big companies, but we will be bigger than many other companies that were ahead of us over the last five years,” Hikma CEO Said in a statement.
04 Aug 2025
HM the King’s Support for Youth is an Inspirational Model for Their Empowerment Journey
28 Jul 2025
BBK discloses its financial results for the half year ended 30th June 2025
20 Jul 2025
CBB approves the transfer of the retail banking operations of HSBC Bank Middle East, Bahrain Branch to BBK
08 Jul 2025
BBK proudly launches the third edition of “Grow” and welcomes 20 Bahraini graduates
03 Jul 2025
BBK hosts executive leadership session on digital assets in collaboration with Rain
02 Jul 2025
BBK launches the largest-ever Al Hayrat Prizes, offering BD 5 million to over 2,000 winners
16 Jun 2025
BBK and CrediMax Offer Exclusive 20% Discount on Turkish Airlines Flights for Cardholders
25 May 2025
BBK strengthens commitment to sports development through strategic partnership with Bahrain Basketball Association
This website uses cookies to ensure you get the best experience and by clicking “I Accept” below, you consent to the use of cookies. Learn more